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The larval stage of Echinococcus granulosus causes cystic echinococcosis, a neglected infectious disease that constitutes a major
public health problem in developing countries. Despite being under constant barrage by the immune system, E. granulosus
modulates antiparasite immune responses and persists in the human hosts with detectable humoral and cellular responses against
theparasite. In vitro andinvivoimmunologicalapproaches,togetherwithmolecular biologyandimmunoproteomictechnologies,
providedusexcitinginsightsintothemechanismsinvolvedintheinitiationofE.granulosusinfectionandtheconsequentinduction
andregulationoftheimmuneresponse.Althoughthelastdecadehasclariﬁedmanyaspectsofhost-parasiterelationshipinhuman
cystic echinococcosis, establishing the full mechanisms that cause the disease requires more studies. Here, we review some of the
recent developments and discuss new avenues in this evolving story of E. granulosus infection in man.
1.Introduction
Human immune system has evolved specialized mechanisms
and cell populations to protect us from the full spectrum of
pathogensthatposesverydiﬀerentproblemsfortheimmune
system. Helminthes have developed complex evasion strate-
gies and, when the immune response falls short, it may be
necessary for the host to enter a damage limitation state,
accommodating infection in order to minimize pathology.
Parasite immune evasion mechanisms themselves depend
on a form of molecular dialogue between pathogen and
host and, in turn, many parasites depend on host molecular
signals for their development [1].
During cystic echinococcosis (CE) the host-parasite
relationship is interactive and the outcome of infection
depends on the balance achieved by the combination of the
diﬀerent variables involved with the host immunity and the
E. granulosus avoidance strategies [2]. An understanding of
the biological events occurring during infection is necessary
to visualize the diverse immune stimuli to which the parasite
subjects the host and to deﬁne diagnostic and therapeutic
tools. We discuss in detail these topics in this review.
2.E. granulosus Epidemiology
CE, a chronic endemic helminthic disease caused by infec-
tion with metacestodes (larval stage) of the tapeworm E.
granulosus, is one of the most widespread zoonotic diseases
in humans in both developing and developed countries
[3]. Recently, the World Health Organization included
echinococcosis as part of a Neglected Zoonosis subgroup for
its 2008–2015 strategic plans for the control of neglected
tropical diseases [4, 5]. The distribution of E. granulosus is
worldwide, with only a few areas such as Iceland, Ireland,
and Greenland believed to be free of autochthonous human
CE [6]. CE is prevalent in countries of the temperate zones,
including South America, the entire Mediterranean region,
Russia, central Asia, China, Australia, and parts of Africa
[3, 7–9]. In the USA, most infections are diagnosed in
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is endemic. Sporadic autochthonous transmission is cur-
rently recognized in Alaska, California, Utah, Arizona, and
New Mexico [10].
E. granulosus comprises a number of forms that exhibit
considerable genetic variation [11]. Ten strains of E. granu-
losus (G1–10) have been described with molecular biology
techniques using mitochondrial DNA sequences [12]. These
include the common sheep strain (G1), a Tasmanian sheep
strain (G2), two bovine strains (G3 and G5), a horse strain
(G4), a camel strain (G6), a pig strain (G7), a cervid strain
(G8), a Poland swine strain (G9) [12] ,a n da nE u r a s i a n
reindeer strain (G10). Recent molecular re-evaluation of
Echinococcus species strongly suggests that E. granulosus is
an oversimpliﬁed species. The genotypes G1 to G5 have
been reclassiﬁed into E. granulosus sensu stricto ( G 1t oG 3 ) ,
E. equinus (G4), and E. ortleppi (G5). The genotypes G6
to G10 and the lion strain of E. granulosus (formerly E.
felidis)h a v et ob er e - e v a l u a t e d[ 13]. The sheep strain (G1)
has a worldwide geographical distribution, speciﬁcally it is
widely spread in North Africa and has a natural circulation
in some European countries such as Italy [14]; this strain
is commonly associated with human infections. G2 strain
is geographical distributed in Tasmania and Argentina but
there are recent observations of the emergence of the
presence of this strain also in some endemic European
countries as Bulgaria, Italy, France, Portugal, and Spain.
G3 strain has a major distribution in Asia and in more
endemic European countries. The “cervid” genotype (G8)
cycle involves wolves, dogs, mooses and reindeers [12].
Despite the increasing epidemiological reports, available
information on CE is still incomplete and is insuﬃcient
to assess properly its world epidemiology. CE importance
tends to be underestimated due to underreporting and to
the lack of compulsory notiﬁcation. To note, the report-
ing of incidental cases is mandatory in most of the EU
member countries except Denmark and Italy [15]. These
facts strongly recommend the convenience of maintaining
and/or intensifying the control measures currently in place
in order to consolidate the progress achieved and to avoid
the recrudescence of the disease.
3.Echinococcus Metacestodes
3.1. E. granulosus Biology. The complex cycle of the para-
site can explain the intricate host-parasite relationship. E.
granulosus is a small tapeworm (rarely exceeding 7mm in
length) that lives ﬁrmly attached to the mucosa of the
small intestine in deﬁnitive hosts, usually dogs, where the
adult-stage reaches sexual maturity within 4 to 5 weeks.
This is followed by the shedding of gravid proglottids (each
containing several hundred eggs) and/or of released eggs
in the feces of deﬁnitive hosts. After being ingested by the
intermediate host, eggs release embryos (oncospheres) that
penetrate the gut wall, travel via blood or lymph, and are
trapped in the liver, lungs, and other sites where cystic
development begins. This process involves transformation of
the oncospheral stage to reach the metacestode stage.
E. granulosus typically develops as a large unilocular,
turgid cyst, which grows through an increase in diameter
from less than 1 to 5cm each year. This general structure
can be thought to allow a permanent low ratio between
totalparasitecellularvolumeandhost-exposedarea,through
linear growth that can exceed three orders of magnitude.
Hydatidcystisusuallysurroundedbyahost-derivedcollagen
capsule (adventitial layer), but can also been circled by host
inﬂammatory cells. Metacestode (hydatid cyst) is bounded
by the hydatid cyst wall, which comprises an inner cellular
layer (germinal layer) and an outer protective acellular layer
(laminated layer). The germinal layer (GL) gives rise towards
thecystcavitytocellularbudsthatuponvesiculationbecome
brood capsules, and in turn bud towards their inside to
generate protoscoleces. The GL exposes towards the outside
the apical plasma membrane of its syncytial tegument,
which carries truncated microtriches. The GL has additional,
nonsyncytial cell types, including muscle, glycogen-storage,
and undiﬀerentiated cells. Towards the cyst cavity, there is
neither a syncytial organization nor junctional complexes
between cells, so that the intercellular ﬂuid of the germinal
layer is apparently continuous with the cyst/vesicle ﬂuid
[16, 17].
In spite of being widely considered the crucial element
of host-parasite interfaces, the laminated layer (LL), a
structure only found in the genus Echinococcus,i sp o o r l y
understood. In fact, it is still often called “chitinous,”
“hyaline,” or “cuticular” layer, or said to be composed of
polysaccharides. However, over the past few years the LL was
found to be comprised of mucins bearing deﬁned galactose-
rich carbohydrates, and accompanied by calcium inositol
hexakisphosphate deposits. A recent review discusses the
architecture and biosynthesis of this unusual structure [18].
The cyst cavity is ﬁlled with hydatid cyst ﬂuid (HCF) that
is the main factor responsible for the antigenic stimulation.
The hydatid liquid is clean and clear, “as well as the clean
water from its natural source,” containing secretions from
both the parasite and host and all the elements from the
“inner wall” of the cyst, named hydatid sand [19]. It has an
identical composition to that of the host’s serum (Na, K, Cl,
CO2, a density between 1.008 and 1.015, alkaline pH) and
some speciﬁc proteins that confer antigenic properties such
as Ag5 and AgB.
3.2. E. granulosus Natural History. The natural history of
E. granulosus cysts and its clinical implications comprises
various developmental stages. The initial stage, primary
infection, is always asymptomatic. During this stage, small
(<5cm) well-encapsulated cysts develop in organ sites,
where they persist inducing no pathologic consequences. In
humans, the hydatid cysts are localized in approximately
two-thirds of casesin theliver and in about20% in thelungs,
and less frequently in the kidneys, spleen, heart, and bone.
Some 20–40% of patients have multiple cysts or multiple
organ involvement. After an undeﬁned incubation period
lasting months or years, if cysts exert pressure on adjacent
tissue and induce other pathologic events, the infection may
became symptomatic. Because hydatid cysts grow slowly, the
host often tolerates it remarkably well. Patients with CE may
come to clinical attention only when a large cyst mechani-
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miscellaneous symptoms such as eosinophilia develop, or
when the cyst accidentally ruptures thus triggering acute
hypersensitivity reactions. Cysts or a cystic mass may also be
discovered by chance during body scanning or surgery, or for
other clinical complications [19]. During the outcome of the
infection, several events can occur into the cyst: the death
of the parasite due to dysfunction of the GL (detachment
or aging), the “cyst’s wall” ﬁssure due to detachment of
membranes or micro traumatisms, the transformation of
scolecesintovesicles(vesiculation).Thesenewvesicles,called
oﬀspring or “daughter” vesicles, live into the hydatid ﬂuid
and have the same constitution as well the same mission of
the mother vesicle and occasionally form within larger cysts.
Therefore, in this way, protoscoleces may develop into either
a new cyst or an adult parasite.
The extensive variation at the genetic level may inﬂuence
E. granulosus life development rate, cycle patterns, host
speciﬁcity, antigenicity, transmission dynamics, sensitivity
to chemotherapeutic agents, and pathology with important
implications for the design and development of vaccines,
diagnostic reagents and drugs. To note, human infection
with G8 strain presents a predominantly pulmonary local-
ization, slower and more benign growth, and less frequent
occurrence of clinical complications than reported for other
strain genotypes [10]. Zhang and McManus have recently
extensively reviewed a detailed account of genetic variation
in Echinococcus and its implications [20].
4.E. granulosus Antigens
Sincethe1960s,researchonCEhasbeenfocusedontheiden-
tiﬁcation of immunologically important proteins, especially
potential immunodiagnostic or vaccine candidates. Because
of the expression of diﬀerent antigens during the diﬀerent
developmental stages, the human host responds indepen-
dently to antigenic stimuli of the invading oncosphere, the
metacestode in transformation from the oncosphere, and
ﬁnally, the mature metacestode (larvae) [2]. E. granulosus
immunology has been divided into an “establishment”
phase during which the parasite is most susceptible to host
eﬀectors, and an “established metacestode” phase during
which the parasite elicits chronic disease. In the early stages
of echinococcal development, cellular responses may play a
crucial role in protection against infection [21].
Older studies reported that the oncospheres stimulate
a strong immunity to a challenge infection [22]. Strong
antibody responses against puriﬁed oncosphere proteins
have been reported also in sera from experimentally infected
sheep [23]. Most recent experiments in mice showed that
a second oncospheral challenge 21 days after the primary
infection with E. granulosus produced very high levels of
protection but with a very low antibody response [24].
Therefore, because the oncosphere is known to be associ-
ated with the protective immune response, understanding
the mechanisms whereby protective antibodies against the
oncosphere act, is of fundamental importance in developing
highly eﬀective vaccine against E. granulosus [25]. The
results of Heath and Lawrence [23] settled the basis for the
development of the Eg95 vaccine in ruminants [26, 27].
The LL, an insoluble and unusual biological structure,
is the crucial element of host-parasite interface in larval
echinococcosis. Because of its massive carbohydrate-rich
structure and resistance to proteolysis, it contains few T-
cellepitopesandabundantT-independentanti-carbohydrate
antibodies. Consequently, the innate immunity induces a
noninﬂammatory response and the adaptative immunity
induces a humoral response characterized by low-avidity
antibodies speciﬁc for α-galactose [28]. The history of
LL represents an example of our evolving knowledge in
the immunological mechanisms that E. granulosus takes to
survive in the host. It has been fascinating to arrive at
explanations for observations that lay forgotten in papers
published decades back [29, 30]. In particular, in 1974,
we have observed that sera from patients with pulmonary
cyst localization presented antibodies against a glycoprotein
antigen (α-galactosyl residue) isolated from the hydatid
membrane. This antigen showed a high P1 blood group
activity thus suggesting an intriguing role for the hydatid
membrane in the host-parasite relationship [30]. Later, P1
blood antigen has been also identiﬁed in protoscolex [31]. A
recent review describes in depth the modern studies on the
biochemistry of LL that allowed a more informed analysis of
its immunology [28]. The major immunodiagnostic protein
antigens are present in HCF [32]. However, if T-independent
anti-carbohydrate responses are included, the laminated
layer may instead be the major source of antigens [28]. The
GL of the cyst is a barrier against immune competent cells
of the host. It is generally thought that damages in the GL,
like ﬁssures or rupture, induce an antigenic stimulation.
Whenthisantigenicstimulationoccurs,thereisacontinuous
elevation of the immunologic values for an indeterminate
time. This elevation also happens after the cyst manipulation
(surgery, puncture, etc.) [33].
Extensive studies have focused on hydatid ﬂuid antigens
that still represent the main antigenic source for hydatid dis-
ease diagnosis. At the present time, despite the large number
of studies, the parasitic antigens present in HCF that have
majorimmunodiagnosticvalueindetectingE.granulosusare
antigen 5 (Ag5) and antigen B (AgB) [34, 35]. Native Ag5, a
400kDa thermolabile glycoprotein produces two subunits at
55 and 65kDa in sodium-dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) under nonreducing con-
ditions and two subunits at 38/39 and 22–24kDa under
reducing conditions [36–38]. The biological role of Ag5
is almost completely unknown, although its elevated con-
centration in HCF suggests a relevant function in the
development of the metacestode. The 38/39kDa component
with phosphorylcholine epitopes may be responsible for a
large proportion of cross-reactions with sera from patients
infected with nematodes, cestodes, and trematodes [36–39].
The 38kDa subunit is closely related to serine proteases of
the trypsin family, but has no detectable proteolytic activity
[40]. Studies by sequencing of the N-terminal fraction of
the 38kDa subunit revealed a single amino acid sequence
with alternative residues at some positions, demonstrating
that Ag5 is present in diﬀerent isoforms [41]. Regarding
the 22kDa subunit, the heparan sulphate proteoglycans and
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provide binding targets for the Ag5 molecule [40]. These
would target the antigen and ensure its localization in the
host tissue surrounding the metacestode, or otherwise, the
mucosal epithelium of the E. granulosus deﬁnitive host. Ag5
has been widely used in the serodiagnosis of human CE,
particularly by means of the identiﬁcation of a precipitation
line (arc 5) in immunoelectrophoresis assays [32]. Gonz´ alez-
Sapienza et al., identiﬁed and cloned a metacestode-speciﬁc
component (named P29) immunologically related to, but
distinct from, Ag5 [42]. This ﬁnding would imply that much
of the information derived from studies carried out using
antibodies to Ag5 could be equivocal because of the cross-
reactivity between both Ag5 and P29 [43].
Native AgB, a 160kDa thermostable lipoprotein, pro-
duces three main subunits at 8/12, 16, and 20kDa in
SDS-PAGE under reducing and nonreducing conditions as
well as other mass subunits, probably polymers of the
8/12kDa subunit [44]. The 8/12kDa subunit induces a
good humoral and cellular response [45]. Even though the
8/12kDasubunitofAgBiscross-reactiveinahighpercentage
of patients with alveolar echinococcosis sera and in a small
percentage of patients with cysticercosis, native AgB is of
high immunodiagnostic value [32, 39, 46]. The oligomeric
organisation of the E. granulosus AgB (EgAgB) was further
investigatedbyGonz´ alezetal.[47],whoanalysedthesubunit
composition of EgAgB in HCF by comparing the amino acid
sequence of tryptic peptides isolated from the 8, 16, and
24kDa subunit bands of native EgAgB with that of the 8kDa
subunit monomers and found that the 8kDa band contained
at least two components, which constituted the building
blocksofthehighermolecularweightsubunitbands.Further
progress towards characterising AgB came from experiments
using DNA cloning [44, 48, 49]. Using this technique,
Shepherd et al. [50] reported a cDNA clone encoding the
carboxy-terminal of the 12 (8)kDa subunit of antigen B
and Frosch et al. [51] described its complete sequence
(AgB/8 or EgAgB8/1). Nucleotide variations are present at
a conserved position between AgB/8 cDNA sequences from
diﬀerent isolates, indicating that this gene is polymorphic.
Others later isolated a cDNA clone coding for a second
8kDa subunit of AgB (EgAgB8/2) [52]. Speciﬁc antibodies
against both antigens recognized all AgB bands in western
blot, and peptide sequencing revealed that both antigens are
components of the native AgB subunits [47]. Together these
results show that AgB is made up of subunits encoded by
at least two diﬀerent genes. Molecular studies now show
that E. granulosus AgB is encoded by a multigene family
having at least ﬁve gene loci (B1–B5), each one consisting of
several minor variants that phylogenetic tools grouped into
two clusters: EgAgB1/B3/B5 and EgAgB2/B4 [51, 53–56].
A more recent phylogenetic analysis failed to discriminate
betweentheisoformsEgAgB3andEgAgB5[57].Theputative
protein isoforms encoded by the ﬁve EgAgB genes diﬀer in
amino acid sequence (44–81%). Switching from one isoform
to another could be among the mechanisms parasites use
to evade the host’s immune response and to modulate
periparasitic inﬂammatory reactions [55]. Recently, Muzulin
et al. showed that E. granulosus strains diﬀer in the type
of genomic and transcribed EgAgB sequences, reinforcing
previous evidence that the AgB gene family is highly
polymorphic [49]. How this variation aﬀects the way each
strain adapts to its speciﬁc intermediate host, and whether it
inﬂuencesAgB’spotentialasadiagnostictoolremainmatters
for future studies. In contrast with previous data, showing
that E. granulosus strains diﬀer in the types of genomic
and transcribed EgAgB sequences, Zhang et al. found that
the EgAgB gene family comprises at least ten unique genes,
each of them was identical in both larval and adult E.
granulosus isolates collected from two diﬀerent continents
[58]. DNA alignment comparisons with EgAgB sequences
depositedinGenBankdatabasesshowedthateachgeneinthe
gene family is highly conserved within E. granulosus,w h i c h
contradicts previous studies claiming signiﬁcant variation
and polymorphism in EgAgB. Quantitative PCR analysis
revealed that the genes were diﬀerentially expressed in
diﬀerent life-cycle stages of E. granulosus with EgAgB3
expressed predominantly in all stages. Finally, Chemale
et al. [59] characterising the properties of native EgAgB
to bind hydrophobic ligands and comparing the activity
of two of the 8kDa subunit monomers (rEgAgB8/1 and
rEgAgB8/2), found that the hydrophobic ligand binding
properties of EgAgB diﬀer from the helix-rich hydrophobic
ligand binding properties displayed by proteins from other
cestodes. Because many of these proteins are immunogenic
and some are involved in lipid detoxiﬁcation, transport, and
metabolism with their fatty acid binding properties, AgB
could be involved in the process of parasite survival in host
microenvironment.
Similar to E. granulosus, AgB also exists in the cyst
ﬂuid of E. multilocularis a n dA g Bg e n e sa r ee x p r e s s e di n
a developmentally regulated manner in E. multilocularis
vesicles, protoscoleces, and immature adult worms [44].
In the 1990s it had become apparent that the new
techniques in molecular biology oﬀered a new approach to
overcome some problems and several recombinant antigens
have been produced and used as molecular tools in the
immunodiagnosis of CE [60]( Table 1). In a series of
molecularstudies,wescreenedanE.granulosuscDNAlibrary
with IgE from patients with CE who had acute cutaneous
allergic manifestations and we identiﬁed three conserved
constitutive proteins: EgEF-1 β/δ, EA21, and Eg2HSP70 [61–
64].
Later, we screened an E. granulosus cDNA library with
IgG4 from patients with active disease and with IgG1 from
patients with inactive disease. By screening with IgG4 from
patients with active disease, we obtained two proteins. The
ﬁrst is present on the protoscolex tegument and on the GL of
cyst wall (EgTeg) and the second protein has 19.0kDa (Eg19)
[65, 66]. By screening the E. granulosus cDNA library with
IgG1 from patients with inactive disease, we obtained EgTPx
[67].
5.E. granulosus andAntibody Responses
There are extensive data on immune responses against the
hydatid cyst both from studies on patients with E. granulosus
infection and from experimentally infected animals [22].
The established parasite produces signiﬁcant quantities ofClinical and Developmental Immunology 5
Table 1: Main Echinococcus granulosus antigenic molecules identiﬁed and characterized, and/or recombinantly expressed.
Antigen Name References
A n t i g e n5 A g 5 C a p r o ne ta l .[ 36]
Antigen B AgB Lightowlers et al. [35]
Echinococcus granulosus 29kDa P-29 Gonz´ ales et al. [42]
Echinococcus granulosus paramyosin EG36 M¨ uhlschlegel et al. [68]
rEgG5 rEgG5 Lightowlers et al. [26]; Li et al. [69]
Thioredoxin peroxidase TPx Salinas et al. [70]; Margutti et al. [67]
EgA31 EgA31 Fu et al. [71]
Elongation factor 1β/δ EgEF-1 β/δ Margutti et al. [61]
Cyclophilin EA21 Ortona et al. [63]
EpC1 EpC1 Li et al. [72]
Tropomyosin Trp Esteves et al. [73]
Heat shock protein 70 HSP70 Ortona et al. [64]
Echinococcus granulosus Tegumental antigen EgTeg Ortona et al. [65]
Eg19 Eg19 Delunardo et al. [66]
Heat shock protein 20 HSP20 Vacirca et al. [74]
molecules that modulate the immune responses and these
include both humoral and cellular immune response against
the parasite.
Although the data are limited, there is, nevertheless, clear
evidence from experiments with animals challenged with E.
granulosus eggs or oncospheres that infected hosts produce
signiﬁcant immune responses, including antibodies and T
cell responses generated by lymphocytes.
The earliest IgG response to oncospheral antigens
appears after 11 weeks in mice and sheep challenged with
eggs or oncospheres of E. granulosus [23]. These anti-
oncospheral antibodies play a major role in parasite killing
and are central to the protective immune response against E.
granulosus.
Numerous studies demonstrated that E. granulosus HCF
induces a strong humoral response in humans. Even if sera
from patients with CE contain abundant circulating IgG,
IgM, and IgE antibodies to E. granulosus antigens, none of
these antibodies is associated with protection [75]. Because
IgG antibodies, that retain ﬂoating levels for many years even
after “cure,” cannot be considered as immunological markers
of the outcome of therapy, the analysis of IgG subclass, that
vary during the outcome of the disease, has been considered
for a long time useful in follow-up [18]. In contrast with
these results, we demonstrated that the expression of the
various IgG isotypes remained practically unchanged over
a long-term follow-up, but antibody levels before therapy
diﬀered in the patients grouped according to the outcome
of chemotherapy. IgG isotype expression diﬀered also in
its HCF and AgB binding proﬁles. Hence, although IgG
isotypes cannot be considered as immunological markers
of the outcome of chemotherapy, we concluded that they
might be a useful guide to the clinical management of
CE [76]. Recently Pan et al. demonstrated that because
the expression of AgB2 declines with progression of the
disease, this antigen is a suitable immunological marker for
detection, diagnosis, and progression of the disease [77].
GiventhattheﬁrststudiesofIgGsubclassantibodyresponses
inadvancedhumanCEindicatedaswitchfrompredominant
IgG1 response to IgG4 in CE patients with progress disease,
the peculiar role of IgG4 during CE has been extensively
studied and IgG4 actually are considered as immunological
markers during CE [78]. IgG4 is a subclass associated with
prolonged, chronic infection, that is neither cytophilic nor
complement ﬁxing, is nonfunctional, and binds weakly to
receptors for the Fc portion of immunoglobulins, it may
help the parasite to evade the host immune response [79].
Moreover, parasite-speciﬁc IgG4 antibodies can inhibit IgE-
mediated degranulation of eﬀector cells reducing allergic
pathology in the host [80]. In agreement with these studies,
we found that albendazole-treated patients, who exhibited
a good therapeutic and clinical response to treatment, had
signiﬁcantlylowerlevelsofserumIgG4antibodies,thanpoor
responders or nonresponders whereas IgG1 antibody levels
showed a reverse trend [81, 82]. Later we conﬁrmed the
presence of higher IgG4 and IgE in patients with progressive
disease and higher IgG1 and IgG3 in patients with stable
disease [76].
6.E. granulosus andCytokineInduction
A key question is how E. granulosus that encounter the
immune system can inﬂuence the diﬀerentiation decision.
Th1 and Th2 cells are not precommitted phenotypes but
rather, represent endpoints of a multistep diﬀerentiative
process, whereby a common precursor population acquires
a distinct cytokine secretion proﬁle [83]. During CE, the
evidence concerning antibody levels of IgG4 and IgE iso-
types and frequent eosinophilia, suggested that the immune
response to established E. granulosus infection is Th2 domi-
nated and that Echinococcus antigens modulate polarized T-
cells. Immunological studies conducted in our laboratory,6 Clinical and Developmental Immunology
showing high in vitro production of parasite antigen-driven
IL-4, IL-5, IL-6, IL-10, and IFN-γ by peripheral blood
mononuclear cells (PBMC) isolated from patients with CE,
conﬁrmedthatthehumanimmuneresponsetoE.granulosus
infection is predominantly regulated by Th2 cell activation
but also by the Th1 (or Th0) cell subset. [81, 82]. Data
obtained in E. granulosus experimental infection supported
thehypothesisthatearlyIL-10,secretedbyBcellsinresponse
to nonproteic antigens, may favor parasite-survival and
the establishment of a polarized type-2 cytokine response
[84]. Recent ﬁndings suggested that IL-4/IL-10 impairs the
Th1 protective response and allows the parasite to survive
in hydatid patients [85]. Experimental studies in mice
supported the possible local immunosuppression mediated
by IL-10 and TGF-β as possible mechanism that helps the
parasite in escaping the host cell-mediated response [86].
To note, the probable immune-suppressing eﬀects of
TGF-β (and regulatory T cells) have been shown to be
presentinE.multilocularisexperimentalinfection.Intraperi-
toneal murine E. multilocularis infection induces diﬀer-
entiation of TGF-β-expressing dendritic cells (DCs) that
remainimmatureandmodulatesperitonealCD4+ andCD8+
regulatory T-cell development [87].
Evidences highlighting crucial role of cytokines in
the host-parasite relationship come from studies on
parasite-driven cytokine production in a large number of
albendazole-treated patients with CE. PBMC from patients
who responded to chemotherapy produced high amounts
of IFN-γ (Th1 derived) whereas PBMC from patients who
did not respond produced IL-4 and IL-10 (Th2 derived). We
laterconﬁrmedthisﬁndinginamolecularstudybydetecting
IL-12 p40 mRNA in 86% of successfully treated patients at
the end of chemotherapy. PBMC from patients in whom
therapy failed, expressed weakly IL-4 mRNA before therapy,
and strongly thereafter; PBMC from patients who responded
to therapy expressed higher IFN-γ and TNF-α mRNA values
than patients who did not [88]. Finally, T cell lines from a
patient with an inactive cyst had a Th1 proﬁle whereas T cell
lines derived from patients with active and transitional cyst
had mixed Th1/Th2 and Th0 clones [89]. Since PBMC from
seronegative patients produced no parasite antigen driven-
IL-5 and scarce IL-4 and IL-10, we suggested that during CE
the seronegativity occurs because host or parasite factors or
both preclude Th2 cell activation thus limiting or preventing
production of IL-5, the cytokine that has a critical role in
immunoglobulin expression [90].
Collectively our data indicated that in CE a strong Th2
response correlates with susceptibility to disease (active cyst)
whereas a Th1 response correlates with protective immunity
(inactive cyst) and that Th1 and Th2 responses coexist.
The role of DCs in the immunity of CE and in
the host-parasite relationship has been recently evaluated.
Inﬂammatory mediators or microbial agents promote the
migration of DCs into the secondary lymphoid organs. As
they migrate, DCs mature, lose their Ag-capture ability,
and gain an increased capacity to prime T cells. DC-
parasite interactions are pivotal in triggering and regulating
parasite-induced immunity. DC function is itself modulated
during parasitic infection for the mutual beneﬁt of the
host and of the parasite [91, 92]. E. granulosus hydatid
ﬂuid modulates DC diﬀerentiation and cytokine secretion
[93]. We have demonstrated that E. granulosus hydatid ﬂuid
impairs monocyte precursor diﬀerentiation into immature
DCs rendering them unable to mature when stimulated with
lipopolysaccharides.TheparasitemodulatesalsosentinelDC
maturation, priming them to polarize lymphocytes into Th2
cells [94]. Collectively, these cellular ﬁndings establish that
E. granulosus can directly inﬂuence the components of host
cellular response, T lymphocytes, and DCs.
7.E. granulosus andImmune-Modulating
Molecules
Because E. granulosus inhabits immunocompetent hosts for
prolonged periods it is not surprising that it should possess
modulatormoleculesthatremodelhostresponsestoenhance
its survival. AgB is the principal E. granulosus immune-
modulant antigen [45]. Because it can modulate both
innate and adaptive host immune responses, AgB plays a
prominent role in the immunomodulatory mechanisms that
E. granulosus uses to develop, progress, and cause chronic
disease [2]. To survive in host tissues the parasite must be
able to adapt metabolically to the host microenvironment,
and plentiful AgB in HCF probably guarantees parasite
survival. A large amount of data suggests that AgB directly
immunomodulates the host immune response by inhibiting
PBMC chemotaxis and indirectly by skewing the Th1:Th2
cytokine ratio towards a preferentially Th2 polarization
associated with chronic CE disease.
The 12kDa subunit of AgB is a serine protease inhibitor
with strong chemoattractant activity and with the ability
to inhibit human neutrophil chemotaxis without altering
either random migration or oxidative metabolism [50, 95].
In agreement with the negative immunomodulatory role
suggested for AgB on human neutrophils, when accidentally
released hydatid ﬂuid activates neutrophils, AgB could act as
an interference antigen allowing the released protoscoleces
to develop into secondary cysts [96]. We investigated the role
of AgB in acquired immunity by evaluating AgB-driven Th1
and Th2 cytokine production by PBMC from patients with
CE [95–97]. Patients’ PBMC stimulated with AgB produced
IL-4, IL-13, and low IFN-γ concentrations, but did not
produce IL-12. This Th2 polarization was more evident in
patients with active disease, in whom the stimulus with AgB
increased the imbalance observed in cultures from patients
with inactive disease [89]. Finally, AgB modulates sentinel
DCs maturation, priming those to polarize lymphocytes into
an exclusive Th2 response that beneﬁts the parasite (IL-4
expression). Our data oﬀer a rationale for this polarization
byshowingthatifAgBencountersimmatureDCs,itsuppress
IL-12p70 production by inducing the immunoregulatory
cytokine IL-10. AgB reduces lipopolysaccharide-induced
production of IL-12p70 but not of IL-6, providing further
evidence that it actively modulates DC responsiveness in a
manner favouring a Th2 outcome [94].
In a series of molecular studies, we screened an E.
granulosus cDNA library and we identiﬁed constitutive
proteins (EgEF-1 β/δ, EA21, Eg2HSP70, EgTeg, Eg19, andClinical and Developmental Immunology 7
EgTPx) that appear to have immunomodulant propriety.
The EgEF-1 β/δ intervenes in immunomodulation because
it continues to be released into the hydatid ﬂuid after the
protoscoleces degenerate; in fact, we found a higher percent-
age of antibodies speciﬁc against EgEF-1β/δ in patients with
CE who had inactive cysts than in patients with active cysts
[61, 62]. Also we found that a high percentage of sera from
patients with CE without allergic manifestations had IgG4
antibodies speciﬁc to EA21 whereas patients with allergic
manifestationsshowedIgEspeciﬁctoEA21wesuggestedthat
in CE, as in other parasitic diseases, IgG4 apparently acts to
block pathogenic processes, minimizing severe pathology in
the host [63]. Regarding Eg2HSP70, this antigen seems to
elicit IL-4 production not through its intrinsic ability but by
strengthening, the generalized Th2 polarization previously
established [64].
EgTeg is an immunomodulatory molecule that, as AgB,
contributes to chronic infection by inhibiting chemotaxis
and inducing IL-4 and IgG4 [65]. Regarding Eg19 reactivity,
the percentage of total IgG-, IgG1-, and IgG4-positive
sera were signiﬁcantly higher in sera from patients with
active disease and cyst in multiple sites than from patients
with inactive disease and cyst in the liver. Because anti-
Eg19 antibody concentration decreased over the course of
treatment in sera from patients with cured disease, our data,
conﬁrming the presence of antigens inducing both IgG1 and
IgG4 during active CE, suggest that Eg19 might be a marker
of disease status [66].
EgTPx seems to have an unclear role in immunomod-
ulation, further researches are necessary to clarify precisely
how EgTPx intervenes in immune evasion and whether anti-
EgTPx antibodies can be used to counteract larval survival
and development [67]. In a recent review about the E. mul-
tilocularis parasite-host interplay, Gottstein and Hemphill
described the protein and glycoprotein composition of the
laminated layer and the E/S fraction, including Em2- and
Em492-antigens, two metacestode antigen fractions that
exhibit immunosuppressive or -modulatory properties [98].
An important molecule is the 14-3-3 protein family, small
proteins (30kDa), described and characterized in several
parasites and mostly studied in E. granulosus and E. mul-
tilocularis. In a recent review, Siles-Lucas et al. have deeply
described new data about this protein and its important
implications in the parasite biology and immunology in the
frame of the host-parasite relationship [99].
8. New Perspectives from Proteomic
The advent of proteomics techniques, applied to the analysis
of the protein content of biological ﬂuids, has signiﬁcantly
improved the identiﬁcation and characterization of proteins
from E. granulosus metacestode to use as potential new
diagnostic and prognostic indicators. The use of related
analytical techniques also oﬀers the opportunity to gain
information on regulation, via post-translational modiﬁca-
tion, and on elucidation of the protein expression proﬁle
in diﬀerent parasite stages and in diﬀerent disease stages.
Moreover, proteomics will certainly play an important role
in the study of changes in the protein expression levels of
protoscoleces in response to external factors, such as anti-
helmintic treatment, stress and in the comparative analysis
of cysts from diﬀerent hosts or between active and resting
cysts [100, 101].
The lack of a complete sequenced genome and the pres-
ence of highly abundant host serum proteins prevented for
long time the E. granulosus metacestode proteomic analysis.
However, these negative factors have been at least in part
compensatedby the availability of a comprehensive E. granu-
losus EST database and by the use of an immunopuriﬁcation
approach to enrich samples with proteins from parasite
origin, respectively. Therefore, the strategy of searching not
only in the E. multilocularis EST database but also in the EST
data available from other platyhelminthes allowed to extend
the previously restricted overall repertoire of known proteins
expressed and released by the E. granulosus metacestode
[102].
Chemale et al. [100] reported for the ﬁrst time the
proteomic technique for identiﬁcation of new proteins in
E. granulosus. These authors, using a parasite-enriched frac-
tion from a whole protoscoleces protein extract, identiﬁed
and analyzed by MALDI-TOF-MS 100 prominent protein
spots. They identiﬁed important proteins, such as actin,
tropomyosin, paramyosin, thioredoxin reductase, antigen P-
29,cyclophilin,andtheheatshockproteinshsp70andhsp20.
Three diﬀerent protein spots were identiﬁed as actins, and
this data conﬁrms previous results suggesting the existence
of several actin genes in the E. granulosus genome [103].
More recently, Monteiro et al. [102] analyzed antigens
of E. granulosus during infection of its intermediate bovine
host. They used an immunoproteomic strategy joining
immunoblot immune screening with proteome technolo-
gies involving 2-DE-PAGE and mass spectrometry for the
identiﬁcation of proteins. Parasite proteins were identiﬁed
in diﬀerent metacestode components (94 from protoscolex,
25 from GL, and 20 from HCF). The subsequent search
for antigenic proteins by immunoblot resulted in the iden-
tiﬁcation of many proteins recognized by cystic hydatid
disease patient sera. As well as proteins previously identiﬁed
as antigens (P-29, EgTPx, EgcMDH, HSP70, grp78, actin,
calreticulin, tropomyosin, HSP20, and 14–3–3), the authors
identiﬁed for the ﬁrst time ﬁve antigens: enolase, GST,
putative MVP protein, fructose-bisphosphate aldolase, and
citrate synthase. Moreover, they found proteins that may
contribute to immunoregulatory events such as paramyosin
and tetraspanin, proteins contributing to the establishment
of an E. granulosus chronic infection as AgB and EgTeg.
Aziz et al. [101]u s e dad i ﬀerent proteomic approach:
ﬁrstly, 1D SDS-PAGE gels were used to fractionate HCF
and these were divided into thirty bands and subjected to
LC-MS/MS after in-gel digestion. Secondly, a large quantity
of HCF was analysed using peptide OGE and an LC-
MS/MS protocol that incorporated an extended (2h) LC
step. Using these techniques, they were able to identify 130
protein constituents of HCF from three intermediate hosts
of E. granulosus. Over forty parasite proteins were identiﬁed
in HCF, the most abundant being AgB and Ag5, two
known antigens. As in previous studies [91, 95], thioredoxin
peroxidase and two isoforms of the low-density lipoprotein8 Clinical and Developmental Immunology
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Figure 1: Major components of the immune response to hydatid cyst ﬂuid in the host: Echinococcus granulosus-derived immune modulators
and the main cytokines that regulate this response. Parasite-derived molecules as AgB, EgTeg, and EgEF-1β/δ could elicit a predominant Th2
activation whereas EgTPx and other HCF components can elicit a concomitant Th1/Th2 cell activation.
receptor were identiﬁed and these are likely to aid parasite
survival by protecting against oxidative damage and in the
uptake of sterols and fatty acids from the host, respectively.
Other identiﬁcations included cyclophilin, ferritin, heat
shock proteins, annexin A13, and cathepsin B.
We have exploited the classic immunoproteomic strategy
to identify E. granulosus antigens distinctive of diﬀerent stage
of the disease [74]. Two-dimensional gel electrophoresis (2-
DE)ofHCF,followedbyimmunoblotanalysiswithserafrom
patients with distinct phases of disease enabled us to identify,
by mass spectrometry, HSP20 as a potential marker of active
CE. Immunoblot analysis revealed anti-HSP20 antibodies
in a statistically signiﬁcant higher percentage of sera from
patients with active disease than in sera from patients with
inactive disease. Anti-HSP20 antibody levels signiﬁcantly
decreased over the course of pharmacological treatment in
sera from patients with cured disease, relative to sera from
patients with progressive disease. This proteomic approach
emphasizes the presence of a large number of antigenic
proteins associate to parasite immune evasion during the
development of the disease and highlights the diﬃculty in
understanding the host-parasite relationship.
9. Conclusions
The hydatid cyst secretes and exposes numerous immun-
omodulatory molecules to the host’s immune system.
Throughout the past 30 years, experimental studies probing
the immunobiology of E. granulosus have begun to uncover
an evolving story in which parasite immunomodulating
proteins actively interact with innate and adaptative human
immune processes to reduce the impact of a host response
(Figure 1). The natural history of cyst development indicates
that each cyst is a story in itself and that signiﬁcant eﬀorts
must be made to establish markers of cyst viability and of
nature and intensity of immune response.
Clinical proteomic looks like one of the most conceptu-
ally and scientiﬁcally sound ways of generating and exploit-
ing new biological insights and technologies for the beneﬁt
of patients. Alternative strategies, such as generation of
multiplex quantitative immunoassays, may need to improve
diagnosis, classiﬁcation, prediction of treatment response,
and prognosis of CE disease. In conclusion, the E. granulosus
story is not over yet, but continues.
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